- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GSK plc (GLAXF)
19.5100
-0.8100(-3.99%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
19.5100
19.5100
52 wk Range
15.5400
22.4500
GSK plc (GLAXF) Price Discussion
All relevant comments and GSK plc share chat regarding the GSK LON share news are listed here in the GSK forum. View and contribute to the GSK share chat. Discuss GSK plc share price sentiment, breaking news, GSK share price movements and more.
Note that all comments included here in the GSK plc stock share price forum have met Investing.com UK's comment guidelines.
Note that all comments included here in the GSK plc stock share price forum have met Investing.com UK's comment guidelines.
Citadel shorting everyday
buy buy buy
constant hammering by 2 hedge funds, why
GlaxoSmithKline (GSK) A new article has been published – GSK’s GSK’227 Receives FDA Breakthrough Therapy Designation for Osteosarcoma
Well, as I have said repeatedly over the last few years, GSK is a train crash under CEO Walmsley. GSK had a reputation as the world's leading vaccine developer. Along came COVID and GSK was never in the running. They had an offer of £50bln for the now Haleon and turned it down. Haleon was spun off at half the offer price to the detriment of shareholders. Now GSK is being widely downgraded as an underperforming pharma company and the share price is dropping through the floor while it's closest rival Astrazenica has tripled in value over the last 8 years. The only upside is GSK has settled most Zantac claims, yet the share price still falls. I'm afraid until we get a change of CEO nothing will improve. Train Crash!
it's a screaming buy
as soon as zantac litigation solved 2200 target
looks like gsk has been bombed in lebanon
Any reason why its down after todays string resumts?
Due to less sales than expected in vaccines and one of their products peforming poorly in america. They are also in a lawsuit regarding their heartburn medicines.
GSK is a total train crash under current CEO.
Will it exceed 1800 and stay their is the question
more enough 5 year high. now will it smash through that high is the question.....
Nov 1 call coming correct
Thanks
did anyone act on my call.
triple buy. tgt 1900
All export earners today are going south
Lovely little boost from the Zantec case today. Let's hope the shares kick onwards from here
ITH stock
Bought back all the gsk that I sold back in May. It's a no brainer at this price
You are right. Also the price has been range bound for a decade and we are now near to the lower bound. I've heard similar comments to you nearly ever year when it's price is underperforming
I wish the institutional shareholders would wake up and do something about the management team. Surely with such an abysmal performance over so long GSK must be a takeover target?
I'm only interested in swing trading this counter. If the price doesn't move I'll just collect dividends while waiting for it to bounce. The spinoff of Haleon is a good move as in this day and age companies need to be pure play to get ahead of competition. Consumer healthcare business was a distraction to their management.
new management required
Bloodbath coming
Hi John, it will be worsth ?
When will this carnage start, exacty (02/11/22)
Should have taken the Unilever offer...
It was madness not to.
Demerger yet another damp squib in a long line of failures by Walmsley. She is unprecedented in her ability to talk the talk but to not walk the walk!
This may go up further but I've started to take some profit as precaution. I suspect ulvr may not revise their offer after its sp tanking showing clear sentiments from shareholding to reject this move
Moving closer to my 1800 tgt (posted on March 30). This stock pays very generous dividend I have to say
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.